WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) today announced that the company will host a conference call and webcast on Wednesday, March 13 at 8:30 a.m. Eastern Time to discuss its fourth quarter and year-end 2012 financial results. The call and webcast will follow the release of the fourth quarter financial results before the market opens.
Conference Call Details
To access the live conference call on March 13 at 8:30 a.m. Eastern Time via phone, please dial (877) 845-1016 from the U.S. and Canada, or (708) 290-1155 internationally. Please dial in approximately ten minutes prior to the start of the call.To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the company's website http://investor.bg-medicine.com/events.cfm . Please connect to the website at least 15 minutes prior to the call to allow for any software download that may be necessary. About BG Medicine BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the development and commercialization of novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs. The Company has two products: the BGM Galectin-3® test for use in patients with chronic heart failure is available in the United States and Europe; and the CardioSCORE™ test for the risk prediction of major cardiovascular events will be launched in Europe in the first half of 2013. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.bg-medicine.com and www.galectin-3.com. The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352
CONTACT: Chuck Abdalian EVP & Chief Financial Officer (781) 434-0210
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts